CRUCELL N.V. - positive Testergebnisse

gute News !, Crucell Announces Start of Rabies Antibody Product Clinical Trial 12:36 13.12.06 Leiden, The Netherlands, December 13, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that the rabies monoclonal antibody product it is currently developing has entered a Phase I clinical study in the United States. Crucell has developed a human monoclonal antibody product, a combination of two monoclonal antibodies for the post-exposure prophylaxis (PEP) of rabies, using its MAbstract® and PER.C6® technology. The pre-clinical evaluation of the antibody product was performed in collaboration with the Rabies Program of the Centers for Disease Control and Prevention (CDC) in Atlanta. The Crucell-funded US clinical trial, will be a randomized, double-blind, placebo controlled study in 60 healthy volunteers that will test the antibody product alone in a dose escalation study as well as in combination with a rabi [mehr]

Tradingwettbewerb USA 2004

1 Abrechnung -- Verkauf des Bestandes, 500 ELNK zum EK 10.77 = 5.385,-- 1060 EMRG zum EK 3.21 = 3.402.60 + Cash: 91.00 = Gesamt Cash: 8.878.60 Dieser Betrag wird verteilt auf 2.706 USXP EK 0.82 = 2.218.92 201 RBAKD EK11.00 = 2.211,-- 51.619 IBZT EK 0.043 = 2.219,61 443.930 CTKH EK 0.005 = 2.219,65 GESAMT: 8.869,18 (Restcash: 9.42) So müsste es stimmen.Man ist das kompliziert mit den neuen Regeln.Nichts für das Juristenhirn! "Judex non calculat". Ciao B.L. [mehr]

aktiencheck.de - Forum - Crucell

CRUCELL N.V. - positive Testergebnisse

Tradingwettbewerb USA 2004